HIV gene therapy passes first safety check in tiny study

NCT ID NCT02390297

Ongoing Disease control Sponsor: Calimmune, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 11 people who previously received a gene therapy called Cal-1 for HIV. The goal is to watch for any delayed side effects over many years. Researchers will also check whether the modified cells are still present and active in the blood. It is a safety-only study, not designed to measure how well the therapy controls HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cal-1 (gene-modified CD4+ T cells and/or CD34+ stem cells)
What this could lead to: If successful, this could confirm that Cal-1 gene therapy is safe over many years, supporting its use as a long-term HIV control strategy.
What could go wrong: This is a very small follow-up study (11 people) focused only on safety, not on whether the treatment works. It cannot prove effectiveness, and rare side effects may still emerge later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION RECEIPT OF CAL-1 MODIFIED HEMATOPOIETIC CELLULAR PRODUCTS

Contacts and locations

Locations

Quest Clinical Research

San Francisco, California, 94115, United States
UCLA CARE Center

Los Angeles, California, 90035, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.